200 related articles for article (PubMed ID: 33506810)
1. Early low-molecular-weight heparin administration is associated with shorter time to SARS-CoV-2 swab negativity.
Trunfio M; Salvador E; Gaviraghi A; Audagnotto S; Marinaro L; Motta I; Casciaro R; Ghisetti V; Fava C; Bonora S; Di Perri G; Calcagno A;
Antivir Ther; 2020; 25(6):327-333. PubMed ID: 33506810
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial.
Olagunju A; Fowotade A; Olagunoye A; Ojo TO; Adefuye BO; Fagbamigbe AF; Adebiyi AO; Olagunju OI; Ladipo OT; Akinloye A; Adeagbo BA; Onayade A; Bolaji OO; Happi C; Rannard S; Owen A
Trials; 2021 Jan; 22(1):3. PubMed ID: 33397457
[TBL] [Abstract][Full Text] [Related]
3. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.
Sholzberg M; Tang GH; Negri E; Rahhal H; Kreuziger LB; Pompilio CE; James P; Fralick M; AlHamzah M; Alomran F; Tseng E; Lim G; Lillicrap D; Carrier M; Áinle FN; Beckett A; da Costa BR; Thorpe K; Middeldorp S; Lee A; Cushman M; Jüni P
Trials; 2021 Mar; 22(1):202. PubMed ID: 33691765
[TBL] [Abstract][Full Text] [Related]
4. Low-molecular-weight heparin use in coronavirus disease 2019 is associated with curtailed viral persistence: a retrospective multicentre observational study.
Pereyra D; Heber S; Schrottmaier WC; Santol J; Pirabe A; Schmuckenschlager A; Kammerer K; Ammon D; Sorz T; Fritsch F; Hayden H; Pawelka E; Krüger P; Rumpf B; Traugott MT; Glaser P; Firbas C; Schörgenhofer C; Seitz T; Karolyi M; Pabinger I; Brostjan C; Starlinger P; Weiss G; Bellmann-Weiler R; Salzer HJF; Jilma B; Zoufaly A; Assinger A
Cardiovasc Res; 2021 Dec; 117(14):2807-2820. PubMed ID: 34609480
[TBL] [Abstract][Full Text] [Related]
5. Early treatment with low-molecular-weight heparin reduces mortality rate in SARS-CoV-2 patients.
DE Vito A; Saderi L; Fiore V; Geremia N; Princic E; Fanelli C; Muredda AA; Panu Napodano C; Moi G; Maida I; Fois AG; Sotgiu G; Madeddu G; Babudieri S
Panminerva Med; 2023 Sep; 65(3):286-291. PubMed ID: 35622392
[TBL] [Abstract][Full Text] [Related]
6. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study.
Lian N; Xie H; Lin S; Huang J; Zhao J; Lin Q
Clin Microbiol Infect; 2020 Jul; 26(7):917-921. PubMed ID: 32344167
[TBL] [Abstract][Full Text] [Related]
7. Vaccination and Antiviral Treatment Reduce the Time to Negative SARS-CoV-2 Swab: A Real-Life Study.
De Vito A; Moi G; Saderi L; Puci MV; Colpani A; Firino L; Puggioni A; Uzzau S; Babudieri S; Sotgiu G; Madeddu G
Viruses; 2023 Oct; 15(11):. PubMed ID: 38005858
[TBL] [Abstract][Full Text] [Related]
8. Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial.
Garcia PJ; Mundaca H; Ugarte-Gil C; Leon P; Malaga G; Chaccour C; Carcamo CP
Trials; 2021 Apr; 22(1):262. PubMed ID: 33836826
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
10. Early Negativization of SARS-CoV-2 Infection by Nasal Spray of Seawater plus Additives: The RENAISSANCE Open-Label Controlled Clinical Trial.
Cegolon L; Mastrangelo G; Emanuelli E; Camerotto R; Spinato G; Frezza D
Pharmaceutics; 2022 Nov; 14(11):. PubMed ID: 36432693
[No Abstract] [Full Text] [Related]
11. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
[TBL] [Abstract][Full Text] [Related]
12. Association between detectable SARS-COV-2 RNA in anal swabs and disease severity in patients with coronavirus disease 2019.
Lin W; Xie Z; Li Y; Li L; Wen C; Cao Y; Chen X; Ou X; Hu F; Li F; Tang X; Cai W; Li L
J Med Virol; 2021 Feb; 93(2):794-802. PubMed ID: 32672840
[TBL] [Abstract][Full Text] [Related]
13. Ivermectin for preventing and treating COVID-19.
Popp M; Stegemann M; Metzendorf MI; Gould S; Kranke P; Meybohm P; Skoetz N; Weibel S
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD015017. PubMed ID: 34318930
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection.
Yan D; Liu XY; Zhu YN; Huang L; Dan BT; Zhang GJ; Gao YH
Eur Respir J; 2020 Jul; 56(1):. PubMed ID: 32430428
[TBL] [Abstract][Full Text] [Related]
15. Inhalation of Low Molecular Weight Heparins as Prophylaxis against SARS-CoV-2.
Eder J; Bermejo-Jambrina M; Vlaming KE; Kaptein TM; Zaderer V; Kemper EM; Wilflingseder D; Reitsma S; de Bree GJ; Cohn DM; Geijtenbeek TBH
mBio; 2022 Dec; 13(6):e0255822. PubMed ID: 36326251
[TBL] [Abstract][Full Text] [Related]
16. Value of swab types and collection time on SARS-COV-2 detection using RT-PCR assay.
Liu M; Li Q; Zhou J; Ai W; Zheng X; Zeng J; Liu Y; Xiang X; Guo R; Li X; Wu X; Xu H; Jiang L; Zhang H; Chen J; Tian L; Luo J; Luo C
J Virol Methods; 2020 Dec; 286():113974. PubMed ID: 32949663
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic testing for SARS-CoV-2 infection in HHT patients: nasopharyngeal versus oropharyngeal swab.
Pagella F; Lizzio R; Ugolini S; Spinozzi G; Maiorano E; Suppressa P; Sabbà C; Matti E
Orphanet J Rare Dis; 2020 Dec; 15(1):350. PubMed ID: 33339521
[TBL] [Abstract][Full Text] [Related]
18. Sensitive tracking of circulating viral RNA through all stages of SARS-CoV-2 infection.
Huang Z; Ning B; Yang HS; Youngquist BM; Niu A; Lyon CJ; Beddingfield BJ; Fears AC; Monk CH; Murrell AE; Bilton SJ; Linhuber JP; Norton EB; Dietrich ML; Yee J; Lai W; Scott JW; Yin XM; Rappaport J; Robinson JE; Saba NS; Roy CJ; Zwezdaryk KJ; Zhao Z; Hu TY
J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33561010
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Niclosamide vs Placebo in SARS-CoV-2 Respiratory Viral Clearance, Viral Shedding, and Duration of Symptoms Among Patients With Mild to Moderate COVID-19: A Phase 2 Randomized Clinical Trial.
Cairns DM; Dulko D; Griffiths JK; Golan Y; Cohen T; Trinquart L; Price LL; Beaulac KR; Selker HP
JAMA Netw Open; 2022 Feb; 5(2):e2144942. PubMed ID: 35138402
[TBL] [Abstract][Full Text] [Related]
20. Clearance and persistence of SARS-CoV-2 RNA in patients with COVID-19.
Carmo A; Pereira-Vaz J; Mota V; Mendes A; Morais C; da Silva AC; Camilo E; Pinto CS; Cunha E; Pereira J; Coucelo M; Martinho P; Correia L; Marques G; Araújo L; Rodrigues F
J Med Virol; 2020 Oct; 92(10):2227-2231. PubMed ID: 32484958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
